[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-failure--chronic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-failure--chronic":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100643503","implementation-trial-in-patients-with-renal-failure-and-diabetes-for-major-adverse-renal-and-cardiovascular-events-100643503",false,"NCT07634718","Implementation Trial In patieNts With rEnal failuRe and diAbetes for Major Adverse reNal and Cardiovascular Events","ITINERANCE","Main inclusion criteria:\n\n* Subject attending a ML participating to the study\n* Subject presenting a HbA1c ≥ 6.5% and an estimated GFR (CKD-EPI formula) in the range 60 to 15 ml\u002Fmin (included) and\u002For albumin to creatinine ratio ≥ 300 mg albumin\u002Fg creatinine (or 30 mg\u002Fmmol creatinine), on the same biological determination.\n\nMain exclusion criteria:\n\n* Subject previously identified as opposed to the use of their medical data and\u002For access of their SNDS data,\n* Subject not registered to the French social security system,\n* Subject with estimated GFR \\\u003C 15 ml\u002Fmin on the day of inclusion","ALL","18 Years","80 Years",{"count":20,"type":21},125000,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical study is to establish if the use of public health-related messages, designed and disseminated to a targeted population, will result in tangible improvements in patient outcomes and healthcare practices.\n\nSpecific health-related messages oriented towards patients, through their biological results and HealthCare Professionals (HCPs), will be sent to participants included in the intervention group. The control group will not receive any health-related message (routine care).\n\nThe aim is to evaluate if this intervention leads to differences in Major Adverse Renal and Cardiovascular Events (MARCE), compared to routine care (no dissemination of health messages) in patients suffering in diabetes and renal failure.",[27,28],"Diabetes","Renal Failure , Chronic",[30,31,32],"implementation","heatlh-related message","Renal and cardiovascular event","NOT_YET_RECRUITING","2026-06-02",{"date":36,"type":37},"2026-06-09","ACTUAL",{"date":39,"type":21},"2026-06",{"date":41,"type":21},"2032-06",{"name":43,"class":44},"Nantes University Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100623517","ultrasound-based-prediction-of-hemodynamic-instability-during-cvvhdf-initiation-100623517","NCT07397663","Ultrasound-Based Prediction of Hemodynamic Instability During CVVHDF Initiation","Prediction of Intradialytic Hypotension at the Initiation of Continuous Venovenous Hemodiafiltration Using Multimodal Ultrasonographic and Hemodynamic Parameters in Intensive Care Unit Patients","US-CVVHDF","Inclusion Criteria:\n\n* Adult patients (≥18 years) admitted to the intensive care unit\n* Indication for continuous venovenous hemodiafiltration\n* Adequate transthoracic echocardiographic image quality\n* Written informed consent obtained from legal representatives\n\nExclusion Criteria:\n\n* Acute coronary syndrome\n* Severe valvular heart disease or pericardial effusion\n* Significant arrhythmias interfering with Doppler measurements\n* Presence of pacemaker, ICD, or ventricular assist device\n* Poor echocardiographic imaging window\n* Life expectancy less than 24 hours",{"count":55,"type":21},80,"1 Year","OBSERVATIONAL","This prospective observational study aims to evaluate the ability of transthoracic echocardiographic and bedside ultrasonographic parameters to predict intradialytic hypotension and hemodynamic instability at the initiation of continuous venovenous hemodiafiltration (CVVHDF) in adult intensive care unit patients.",[28,60,61],"Intradialytic Hypotension","Critical Illness",[60,63,64,65,66,67],"LVOT VTI","CVVHD","Renal Resistive Index","Echocardiography","VExUS","2026-02-11",{"date":70,"type":37},"2026-02-13",{"date":72,"type":21},"2026-02-10",{"date":74,"type":21},"2027-02-10",{"name":76,"class":77},"Bursa Yuksek Ihtisas Training and Research Hospital","OTHER_GOV",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":89,"conditions":90,"keywords":95,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":45},"100568090","phase-4-study-to-compare-the-outcome-of-receiving-continued-immunosuppression-versus-stopping-immunosuppression-at-6-months-to-safely-prevent-human-leukocyte-antigen-hla-sensitization-in-patients-with-late-renal-graft-failure-100568090","NCT06676696","Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure","A Multi-centre, Open, Prospective, Randomized, Parallel-group, 24-month Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure","Inclusion Criteria:\n\n* Patient must be able to understand and provide written informed consent\n* Patients older than 18 years who had received at least one previous renal transplant\n* Patients with a retained kidney graft failed for any reason which survived at least 3 months\n* Patients on dialysis, either hemodialysis or peritoneal dialysis. Patients can be on dialysis for a maximum of 6 months at the time of randomization, as long as the patients have taken an uninterrupted immunosuppressive regimen of calcineurin inhibitors (tacrolimus or cyclosporine) and steroids since dialysis was restarted\n* Patients already relisted or candidates to relist to deceased donor kidney transplantation according to the treating physician criteria\n* Patients taking immunosuppressants tacrolimus or cyclosporine\n* cPRA at the time of randomization ≤ 90%\n\nExclusion Criteria:\n\n* Patients who have received another solid organ transplantation (liver, lung, heart or pancreas)\n* Patients waiting for a living related \u002F unrelated kidney transplant\n* Graft survival of the failed graft lower than 3 months\n* Patients in dialysis more than 6 months at the time of randomization\n* Patients not accomplishing criteria to relist in the transplantation list according to the treating physician criteria\n* Pregnant women\n* Females of childbearing age who have not used or do not plan to use acceptable birth control measures, for the duration of the study. Patients should use one of the acceptable birth control measures recommended in the document \"Recommendations related to contraception and pregnancy testing in clinical trials\" published by the Clinical Trials Facilitation and Coordination Group (CTFG) (version 1.1, published 21\u002F09\u002F2020). Recommended birth control measures include oral, injected or implanted hormonal contraceptive, barrier methods (condom or diaphragm with spermicide), intrauterine device, surgical sterilization, transdermal delivery, or sexual abstinence. If sexually active, the subject must have been using one of the accepted birth control methods at least one month prior to study entry.",{"count":86,"type":21},202,[88],"PHASE4","The goal of this clinical trial is to compare the degree of HLA sensitization at 2 years in patients with late renal graft failure (\\> 3 months) when receiving reduced immunosuppressant treatment versus stopping immunosuppression at 6 months.\n\nThe main question this study aims to answer is:\n\nDoes maintaining long-term immunosuppression in patients with a late renal graft failure (\\> 3 months) safely reduce the risk of HLA sensitization?\n\nTo answer this question, patients will be assigned to a control arm or investigational arm:\n\n* Patients assigned to the control arm will receive standard treatment, in which immunosuppressant treatment is withdrawn after 6 months.\n* Patients assigned to the investigatonal arm will continue immunosuppressant treatment at low doses for 2 years.\n\nPatients recruited in this clinical trial will be followed for up to 2 years. During this time, patients will visit the clinic every 3 months for checkups and tests.",[28,91,92,93,94],"Graft Failure","Graft Rejection","Allograft","Renal Failure Chronic Requiring Dialysis",[96,97,98,99,100],"Renal failure","immunosuppressor","HLA sensitization","Graft failure","Calcineurin inhibitors","RECRUITING","2024-11-05",{"date":104,"type":37},"2024-11-06",{"date":106,"type":37},"2024-01-22",{"date":108,"type":21},"2028-01-31",{"name":110,"class":44},"Hospital Universitari Vall d'Hebron Research Institute"]